An extension trial revealed that long-term anifrolumab treatment improved health status and health-related quality of life in ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

Commercialization building with large pharma contracts secured Further progress on next generation sequencing assays for DNA ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug ...

AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. | AstraZeneca is putting the ...

About half of patients with asthma on tezepelumab had discontinued their daily maintenance oral corticosteroid doses by 52 ...

Nvidia has announced plans to build an AI data center in Sweden. The chipmaker will partner with the Swedish Business ...

EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer: Cambridge, UK Tuesday, May 27, 2025, 15:00 Hrs ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...